Our Position on AMR

We must continue developing new antibiotics, treatments, vaccines and diagnostics to secure modern healthcare and stay ahead of the increasing prevalence of AMR. But, due to the  lack of novel classes of antibiotics in the pipeline, it is imperative to conserve the effectiveness of existing antibiotics. We believe that the industry as a whole must take responsibility and stop pollution from antibiotics production.

        Antibiotics have saved

 

             billions of lives.

 

      Now we must save them

We believe that antibiotics producers should drive higher standards through reviewing their supply chains and push for mechanisms to increase transparency through, for example, a quality mark. But as manufacturers, we cannot win the fight against AMR alone. That is why both the industry and the entire value chain - ingredient producers, pharma companies, insurers, distributors, wholesalers and retailers – should act responsibly and stop buying, using and selling irresponsibly made antibiotics. Environmental criteria on antibiotics manufacturing should become a consideration in the sourcing decisions of buyers, health insurers and governments.

 

Read about our answer to AMR here.

Copyright © 2017 DSM Sinochem Pharmaceuticals

Join the conversation

Follow us on Facebook Follow us on Twitter Follow us on LinkedIn

Antibiotics have saved billions of lives.

            Now we must save them

We believe that antibiotics producers should drive higher standards through reviewing their supply chains and push for mechanisms to increase transparency through, for example, a quality mark. But as manufacturers, we cannot win the fight against AMR alone. That is why both the industry and the entire value chain - ingredient producers, pharma companies, insurers, distributors, wholesalers and retailers – should act responsibly and stop buying, using and selling irresponsibly made antibiotics. Environmental criteria on antibiotics manufacturing should become a consideration in the sourcing decisions of buyers, health insurers and governments.

 

Read about our answer to AMR here.

Antibiotics have saved billions of lives.

              Now we must save them

We must continue developing new antibiotics, treatments, vaccines and diagnostics to secure modern healthcare and stay ahead of the increasing prevalence of AMR. But, due to the  lack of novel classes of antibiotics in the pipeline, it is imperative to conserve the effectiveness of existing antibiotics. We believe that the industry as a whole must take responsibility and stop pollution from antibiotics production.

DSM Sinochem Pharmaceuticals logo

We must continue developing new antibiotics, treatments, vaccines and diagnostics to secure modern healthcare and stay ahead of the increasing prevalence of AMR. But, due to the  lack of novel classes of antibiotics in the pipeline, it is imperative to conserve the effectiveness of existing antibiotics. We believe that the industry as a whole must take responsibility and stop pollution from antibiotics production.

Antibiotics are the foundation of our modern healthcare system. Since the mid-1940s, antibiotics have revolutionized modern healthcare, making organ transplantations, chemotherapy, and surgery possible by effectively fighting off infections. It’s hard to imagine a world without them.

 

More than seventy years later, these applications are in serious jeopardy due to the emergence and spread of so called ‘Superbugs’ - bacteria that become resistant to available and formerly effective antibiotics used to treat infections. Currently, antimicrobial resistance (AMR) is quickly turning into the biggest threat to global health, food security and development - causing many common infections, such as pneumonia, to become resistant to antibiotics that are used to treat them, resulting in long-term illnesses, higher medical costs, and an increase in death rates globally.

Antibiotics have saved

      billions of lives.

Now we must save them